JETi Clinical Data for Percutaneous Mechanical Thrombectomy | Abbott
CARDIOVASCULAR
hamburger
JETi Hydrodynamic Thrombectomy System

Percutaneous mechanical thrombectomy single-session treatment of patients with symptomatic venous thrombosis

Overview: Prospective Pilot Study

Razavi et al., JVIR 2021.

Background
Catheter directed thrombolytics (CDT) often require prolonged exposure to thrombolytic agents which can increase bleed risk. CDT typically requires inpatient care making the treatment inappropriate for outpatient settings.

Objective
To investigate the short-term results of single-session treatment of iliocaval and iliofemoral venous thrombosis using the JETi™ Peripheral Thrombectomy System and evaluate potential for treatment on an outpatient basis.

Methods
Prospective pilot study of 47 patients (53 limbs) who presented with symptomatic iliocaval or iliofemoral venous thromboembolism and subsequently underwent percutaneous mechanical thrombectomy with the intention to treat in a single-session. Obstructive lesions were treated with adjunctive therapy, including balloon angioplasty and stenting, as needed.

Endpoints
Reestablishment of unobstructed flow in a single-session, freedom from major adverse events (MAE), improvement in the clot burden utilizing the VRI scoring system and device-related adverse events.

Clinical Outcomes

Overall, single-session unobstructed flow was reestablished in 89% of limbs with no major adverse events through 30 days. Including patients requiring requiring catheter directed thrombolytics (CDT), restoration of flow was successfully achieved in 94% of treated segments.

Segment Flow Restoration: JETi™ Alone Flow Restoration: JETi™ + Stent*
Iliocaval 86% (12/14) 100% (14/14)
Iliofemoral 75% (27/36) 92% (33/36)
Femoropopliteal 100% (3/3) N/A

*Data includes patients who underwent overnight CDT.

Unobstructed flow was re-established in 89% of limbs in a single-session.

JETi Single Session Thrombosis Treatment Unobstructed Flow Reestablished Data

Single-session treatment with the JETi™ thrombectomy device may reduce the risk of bleeding when compared with CDT and eliminate the need for overnight admission in the majority of cases.

JETi Single Session Thrombosis Treatment Eliminates Overnight Admission Data

Restoration of flow was achieved in 94% of treated segments.

JETi Single Session Thrombosis Treatment Restoration of Flow Data

Reference:

Razavi et al., JVIR. 2021.

Important Safety Information
Request a Demo

MAT-2201502 v1.0

IMPORTANT SAFETY INFORMATION

rx-only-logo  JETi™ All-In-One Peripheral Thrombectomy System


Indications

The JETi™ AIO Peripheral Thrombectomy System is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to sub selectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion.
 

Contraindications

The JETi™ AIO Peripheral Thrombectomy System is contraindicated for use in:

  • Vessels smaller than 4 mm (0.16”)
  • Coronary, pulmonary, and neurovasculature


Warnings

The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, and JETi™ Pump Set contents are supplied sterile using EO. Do not use if the expiration date has passed or the sterile barrier is damaged.

  • The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, JETi™ AIO Non-Sterile Kit, and JETi™ Pump Set contents are for single patient use only. Dispose after use. Do not reuse, reprocess, modify, or resterilize. Reuse, reprocessing, modification, or resterilization may compromise the structural integrity of the device and/or lead to device failure which, may result in patient injury, illness or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness, or death of the patient.
  • The JETi™ AIO Peripheral Thrombectomy System is not approved for use with defibrillation. In the event shock must be delivered to the patient, remove the catheter and clear all connected system components from the patient before delivering shock.
  • Do not use a catheter that has been kinked or damaged.
  • Do not use a pump set if it does not prime.
  • Only use the JETi™ Peripheral Catheter and JETi™ AIO Suction Tubing with the JETi™ AIO Peripheral SDU.
  • Do not mix contrast media in the saline bag.
  • When the catheter is exposed to the arterial system, it should be manipulated while under high-quality fluoroscopic observation.
  • In the event that the catheter becomes blocked or clogged with thrombus, remove and replace the device with a new device.
  • Do not use if package is opened or damaged.
  • To avoid risk of electric shock, the SDU must only be connected to mains power with a protective earth.
  • The power socket-outlet must be located near the device and must be easily accessible.
  • Do not modify or alter the device.
  • Do not step or stand on the base of the device.
  • Do not push or lean against the IV pole.


Precautions

Physicians must read and understand the Instructions for Use (IFU) prior to using the device. The device must be used by physicians skilled in percutaneous, intravascular techniques in a fully equipped catheterization laboratory.
 

Potential Adverse Effects

Potential adverse events include, but are not limited to:

  • Acute closure
  • Aneurysm or pseudo aneurysm
  • Allergic reaction to contrast
  • Arrhythmia
  • Death
  • Embolism (air or device)
  • Embolization (thrombotic)
  • Emergency surgery
  • Access site pain, hemorrhage, or hematoma
  • Infection (systemic/sepsis)
  • Local infection (puncture site)
  • Minimal blood loss
  • Vessel dissection, perforation, or other injury
  • Vessel spasm
  • Thrombosis

JETi™ is a trademark of Walk Vascular. Walk Vascular is a subsidiary of the Abbott Group of Companies.
Manufactured by Walk Vascular LLC 17171 Daimler Street, Irvine CA, 92614 USA

MAT-2116195 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.